SAPNANO Vaccine
Cancer
Pre-clinicalActive
Key Facts
About Immunova Therapeutics
Immunova Therapeutics is a private, preclinical-stage biotech developing a diversified portfolio of cancer immunotherapies, including engineered CAR-T and TCR-T cells, as well as novel vaccine and antibody platforms. The company's proprietary technologies, STEM-T and SAPNANO, aim to enhance T cell persistence and vaccine efficacy, respectively, addressing key challenges in solid tumors and treatment durability. Operating in the competitive but high-growth cell and gene therapy sector, Immunova is positioned to target both hematologic malignancies and solid tumors, though it faces significant technical, regulatory, and funding risks typical of early-stage biotechs.
View full company profileTherapeutic Areas
Other Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| Not Specified (Oncology Focus) | Narwhal Bio | Pre-clinical |
| EDM Platform for Genetic Medicine | Coastar Therapeutics | Pre-clinical |
| CO-1 | Caedo Oncology | Pre-clinical |
| Anti-CD99 monoclonal antibody | Caedo Oncology | Discovery/Pre-clinical |
| Anti-HLA class I monoclonal antibody | Caedo Oncology | Discovery/Pre-clinical |
| Triapine® | Nanopharmaceutics | Clinical |
| Ammonium Tetrathiomolybdate | Nanopharmaceutics | Clinical |
| Aza-TdC | Nanopharmaceutics | Clinical |
| Undisclosed Oncology Program(s) | Cell BioEngines | Phase 1 |
| No-alpha IL-2 Mutein | SarcoMed USA | Pre-clinical |
| PMIS Therapeutic | NaturemiRI | Preclinical/Clinical (unspecified) |
| AUM302 (formerly IBL-302) | Inflection Biosciences | Pre-clinical (partnered) |